Completed PHASE2 INTERVENTIONAL 3-arm NCT00050778

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Sponsor: Bayer

Conditions Multiple Sclerosis, Relapsing-Remitting

Interventions Alemtuzumab 12 mg Alemtuzumab 24 mg Interferon beta-1a

Updated 7 times since 2017 Last updated: Jan 6, 2015 Started: Dec 31, 2002 Primary completion: Sep 30, 2007 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Sclerosis, Relapsing-Remitting and is currently completed. Bayer leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Baltimore, United States , Berkeley, United States , Cambridge, United Kingdom , Columbus, United States , Denver, United States , Detroit, United States , Farmington Hills, United States , Fort Wayne, United States , Grand Rapids, United States and 31 more locations